SEC Form 4 · accession 0001193125-26-281062
NewAmsterdam Pharma Co N.V. · NAMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Louise Frederika Kooij
Officer — Chief Accounting Officer
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001936258
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 22, 2026 | M | 25,000 | $10.90 | A | 49,353 | D | |
| Ordinary Shares | Jun 22, 2026 | M | 15,000 | $11.90 | A | 64,353 | D | |
| Ordinary SharesF1,F2 | Jun 22, 2026 | S | 39,700 | $30.20 | D | 24,653 | D | |
| Ordinary SharesF2 | Jun 22, 2026 | S | 300 | $30.73 | D | 24,353 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F3 | $10.90 | Jun 22, 2026 | M | 25,000 | D | — | Jan 1, 2033 | Ordinary Shares | 25,000 | 43,134 | D |
| Option (right to buy)F4 | $11.90 | Jun 22, 2026 | M | 15,000 | D | — | May 18, 2033 | Ordinary Shares | 15,000 | 35,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F2Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
- F3The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
- F4The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Remarks
Reported transactions executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026.